Market News & Trends
Lilly Receives MHRA Marketing Authorisation for Abemaciclib in Combination With Endocrine Therapy for Adjuvant Treatment of People With HR+, HER2- High-Risk Early Breast Cancer
Eli Lilly and Company recently announced the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation (MA) for abemaciclib in combination with endocrine…
Vetter Achieves a Three-Peat in Winning the Best Managed Companies Award
For the third year in a row, Vetter has won the Best Managed Companies Award. With this three-win feat, the pharmaceutical service provider has once again…
4D pharma Presents Late-Breaking Abstract From Phase 1/2 Trial of MRx-4DP0004 for the Treatment of Asthma
4D pharma plc recently announced the presentation of a late-breaking poster on data from Part A of the Phase 1/2 trial of MRx-4DP0004 for the…
MannKind Corporation Announces Agreement to Acquire V-Go Insulin Delivery Device From Zealand Pharma
MannKind Corporation recently announced it has entered into an agreement with Zealand Pharma A/S to acquire V-Go for $10 million, with additional sales-based milestones plus the cost of certain….
IN8bio Announces Data Emerging From its Recently Unveiled Gamma-Delta T cell “Off-the-Shelf” Induced Pluripotent Stem Cell Platform
IN8bio, Inc. recently announced data emerging from the company’s recently unveiled iPSC-based gamma-delta T cell platform. iPSCs represent a significant step toward next generation approaches…
Codiak Presents New Preclinical Data on Exosome-Based Strategy to Enhance AAV Gene Therapy
Codiak BioSciences, Inc. recently announced new preclinical data on the company’s engEx-AAV discovery program, a novel strategy that aims to leverage exosomes to improve adeno-associated virus (AAV) vector gene….
Nurix Therapeutics Reports Dosing of First Patient in Phase 1 Clinical Trial of a Selective BTK Degrader in Development for B-cell Leukemias & Lymphomas
Nurix Therapeutics, Inc. recently announced the first patient has been dosed in its Phase 1a/1b study to evaluate orally available small molecule NX-5948, a potent…
Catalent Launches UpTempo Virtuoso AAV Platform to Reduce Gene Therapy Development Time & Accelerate Path to Clinic
Catalent recently introduced its new, UpTempo Virtuoso platform process for the development and CGMP manufacturing of adeno-associated viral (AAV) vectors. The UpTempo Virtuoso platform standardizes…
Gerresheimer Boosts Global Production Capabilities With New State-of-the-Art Facilities in India
Gerresheimer has significantly ramped up its glass and plastic production capacities in India. A new modern plant to produce high quality plastic containers and closures was built at the….
Prota Therapeutics Achieves 51% Peanut Allergy Remission Rate, First Company to Validate Significant Quality of Life Improvements Compared With Standard Care
Prota Therapeutics Pty Ltd is the first company to validate significant Health-Related Quality of Life improvements (HRQL), when compared to placebo, in a Phase 2b…
Travere Therapeutics Announces FDA Acceptance & Priority Review of NDA for Sparsentan for the Treatment of IgA Nephropathy
Travere Therapeutics, Inc. recently announced the US FDA has accepted and granted Priority Review of its New Drug Application (NDA) under Subpart H for accelerated…
Lantheus Announces First Patient Dosed in Phase 2 Clinical Trial of NM-01 to Monitor PD-L1 Expression in Non-Small Cell Lung Cancer Patients
Lantheus Holdings, Inc. recently announced the first patient has been dosed in a Phase 2 trial evaluating NM-01, its proprietary technetium 99m SPECT imaging agent…
Akston Biosciences Doses First Participants in Phase 2 Clinical Trial for Shelf-Stable COVID-19 Booster
Akston Biosciences Corporation recently announced it dosed the first set of volunteers in an open-label study of AKS-452, its protein subunit COVID-19 vaccine, as a…
Aptar CSP Technologies’ Activ-Blister Solutions Now Available for Manufacturing in the EMEA Region
Aptar CSP Technologies recently announced a new manufacturing site able to produce its Activ-Blister™ Solutions for oral slide dose drugs in Europe. The move is part of….
Pneumagen Announces Positive Top Line Results From Phase 1 Study Evaluating a Product Designed for the Prevention & Treatment of Viral Respiratory Tract Infections
Pneumagen recently reported positive topline data from a Phase 1 study with Neumifil designed to evaluate safety and tolerability in healthy volunteers. The Phase 1, single…
NGM Bio Announces Initiation of Phase 1/1b Clinical Study for the Treatment of Patients With Advanced Solid Tumors
NGM Biopharmaceuticals, Inc. recently announced it has initiated a Phase 1/1b clinical study of NGM438 for the treatment of patients with advanced solid tumors. With…
Update on Positive Pre-Clinical Results From AIM Biologicals Development Program for the Potential Treatment of Parkinson’s Disease
Aeterna Zentaris Inc. recently provided an update on the positive results from pre-clinical studies of Aeterna’s Autoimmunity Modifying Biologicals (AIM Biologicals), for the potential treatment of Parkinson’s Disease (PD)…..
Vallon Pharmaceuticals Reports Additional Pharmacokinetic & Pharmacodynamic Data From SEAL Study of ADAIR
Vallon Pharmaceuticals, Inc. recently reported additional results from the SEAL study evaluating the abuse potential of ADAIR. ADAIR is the company’s proprietary abuse-deterrent formulation of…
PCI Pharma Services Announces Major Manufacturing Expansion with $100-Million Investment
PCI Pharma Services recently announced a major expansion of capabilities and capacity in aseptic liquid fill-finish and sterile lyophilization technology with the investment of $100 million into the….
Artax Biopharma Closes Financing to Advance Clinical-Stage, First-in-Class Oral Immunomodulator to Treat T Cell-Mediated Diseases
Artax Biopharma, Inc. recently announced the close of a $26-million financing round to develop AX-158, the company’s first oral small molecule immunomodulating agent…..
